Search
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalEtravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). … On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnIt was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Aceprometazine
go.drugbank.com/drugs/DB01615ExperimentalAceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.
LC16M8
go.drugbank.com/drugs/DB05019InvestigationalLC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in ...
TGAAC09
go.drugbank.com/drugs/DB06363InvestigationaltgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.
Adinazolam
go.drugbank.com/drugs/DB00546ExperimentalIt has never been approved by the FDA for clinical use.
Deferitazole
go.drugbank.com/drugs/DB13120InvestigationalDeferitazole is an iron chelator. … It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Synonyms: Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)